Yael Kenen

Yael is an executive in the pharma and medical device industry with a demonstrated ability for excellence and valuable results in clinical, medical, and regulatory affairs. In Epitomee, Yael is responsible for Clinical Affairs, leading the clinical development of the company products and executing the company’s entire clinical studies. Before joining Epitomee in 2020 Yael effectively directed and managed professional international teams and played a leading role in obtaining global marketing authorization for Teva’s second ethical drug, Azilect®. She executed the company’s entire clinical studies program for the New Drug Application and lead the clinical-regulation interactions with the FDA and EMEA. Yael was COO at TransPharma Medical, Ltd., and CEO at Lacrima Medical, Ltd., Yael established and has managed the medical and clinical department at Cellect Biotechnology, an innovative cell therapy technology in the area of Oncology and Immunology. Yael holds a Ph.D. from the Hebrew University, MBA from the Technion, and is a visiting fellow in NHLBI (NIH institute).